Small molecule agonists and antagonists of NR2F6 activity in humans

A pharmaceutical composition comprising a pharmaceutical compound in solid form, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, diluent, or carrier, wherein the pharmaceutical compound has a structure of Formula (II),

• wherein R2 is a halogen, an alkyl group, a substituted alkyl group, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, or a nitrile, and R1 is H, a halogen, an alkyl group, a substituted alkyl group, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, or a nitrile.